Sodium selenate - Velacor Therapeutics

Drug Profile

Sodium selenate - Velacor Therapeutics

Alternative Names: VEL-015

Latest Information Update: 20 Jul 2015

Price : $50

At a glance

  • Originator Velacor Therapeutics
  • Class Antidementias
  • Mechanism of Action Protein phosphatase 2A stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 20 Jul 2015 No recent reports on development identified - Phase-II for Alzheimer's disease (Early-stage disease) in Australia (PO)
  • 19 Feb 2013 Velacore Therapeutics initiates enrolment in a phase II trial for Alzheimer's disease (early-stage disease) in Australia (ACTRN12613000170729)
  • 16 Nov 2011 Phase-II clinical trials in Alzheimer's disease (early-stage disease) in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top